Table 5. Prognostic factors for disease-specific survival and disease-free survival in a subgroup of 448 patients with luminal type breast cancer.
| Variables | Disease-specific survival | Disease-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysisa (P value) |
Multivariate analysisb | Univariate analysisa (P value) |
Multivariate analysisb | |||||
| Hazard ratio (95% CI) | Relative risk | P value | Hazard ratio (95% CI) | Relative risk | P value | |||
| Nuclear grade | 0.616 | − | − | − | 0.264 | − | − | − |
| HER2 positive | 0.156 | − | − | − | 0.248 | − | − | − |
| Multiplicity | 0.578 | − | − | − | 0.053 | 0.313–3.782 | 1.088 | 0.895 |
| Histologic grade (reference 1) | 0.169 | − | − | − | 0.009 | 0.331 | ||
| 2 | − | − | − | 0.309–1.811 | 0.747 | 0.519 | ||
| 3 | − | − | − | 0.535–3.759 | 1.418 | 0.483 | ||
| Age (>50 years) | 0.015 | 1.028–4.019 | 2.032 | 0.042 | 0.045 | 0.961–3.830 | 1.919 | 0.065 |
| Perineural invasion | 0.118 | − | − | − | 0.381 | − | − | − |
| Lymphovascular invasion | <0.001 | 0.663–3.382 | 1.497 | 0.331 | 0.001 | 0.604–3.179 | 1.386 | 0.441 |
| T stage (reference 1) | <0.001 | 0.003 | <0.001 | 0.003 | ||||
| 2 | 0.544–2.684 | 1.208 | 0.643 | 0.550–2.783 | 1.237 | 0.607 | ||
| 3 | 0.991–7.111 | 2.655 | 0.052 | 1.087–8.256 | 2.996 | 0.034 | ||
| 4 | 5.018–482.445 | 49.203 | 0.001 | 4.781–488.357 | 48.320 | 0.607 | ||
| Lymph node metastasis | <0.001 | 1.257–7.667 | 3.104 | 0.014 | 0.001 | 1.244–7.624 | 3.080 | 0.015 |
| Distant metastasis (M1) | <0.001 | 1.509–16.715 | 5.021 | 0.009 | <0.001 | 1.603–17.433 | 5.286 | 0.006 |
| NLR>1.34 | 0.048 | 0.591–3.776 | 1.493 | 0.397 | 0.044 | 0.550–3.525 | 1.392 | 0.485 |
| dNLR>1.34 | 0.130 | − | − | − | 0.102 | − | − | − |
| PLR.>185.5 | <0.001 | 1.905–8.562 | 4.039 | <0.001 | <0.001 | 2.108–10.497 | 4.704 | <0.001 |
| LMR≤3.11 | 0.004 | 0.165–1.308 | 0.465 | 0.147 | 0.091 | 0.177–1.574 | 0.527 | 0.251 |
NLR, neutrophil-lymphocyte ratio; dNLR, derived neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio.
aPerformed using the Kaplan-Meier survival analysis model and log-rank test; values of P<0.10 in the univariate analysis were included in a multivariate analysis.
bPerformed using the Cox proportional hazards model.